The Trump administration has secured voluntary agreements with nine major pharmaceutical companies Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech (Roche), Gilead Sciences, GSK, Merck, Novartis, and Sanofi to provide deep discounts on select medications via the upcoming TrumpRx.gov platform and align prices with most-favored-nation (MFN) levels for Medicaid and new launches.
Glimpse:
Announced December 19, 2025, these deals bring total participating firms to 14, offering cash-pay patients reductions up to 85% (e.g., Novartis’ Mayzent from $9,987 to $1,137 monthly). In exchange, companies receive three-year tariff exemptions and commit to over $150 billion in U.S. investments. TrumpRx.gov launches January 2026 as a direct-to-consumer portal, targeting uninsured/high-deductible patients while applying MFN to Medicaid.
President Donald Trump has delivered a major win for American patients by announcing agreements with nine additional pharmaceutical powerhouses to lower prescription drug prices significantly. The deals, unveiled at a White House event on December 19, 2025, expand the TrumpRx program and enforce most-favored-nation (MFN) pricing ensuring U.S. costs match or beat the lowest in comparable developed nations.
The nine companies Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi join prior participants (Pfizer, Eli Lilly, Novo Nordisk, AstraZeneca, EMD Serono), covering a vast array of treatments for cholesterol, diabetes, multiple sclerosis, blood thinners, HIV, hepatitis C, flu, and more.
Key discounted examples on TrumpRx.gov (launching January 2026):
Amgen’s Repatha (cholesterol): $573 → $239 monthly.
Merck’s Januvia (diabetes): ~$330 → $100.
Novartis’ Mayzent (MS): $9,987 → $1,137.
Sanofi’s Plavix (blood thinner): $756 → $16; insulins at $35/month.
Gilead’s Epclusa (Hep C cure): Sharply reduced.
Genentech’s Xofluza (flu): Substantial cuts.
The platform redirects users to manufacturers’ sites for cash purchases (oral meds only; no injectables/infusions). Insured patients may find copays cheaper, and purchases won’t count toward deductibles primarily aiding uninsured or high-deductible plans.
Broader commitments: MFN pricing for Medicaid (saving millions), parity for new U.S. launches, and $150+ billion in domestic manufacturing/R&Dqualifying for tariff relief.
This follows Trump’s May 2025 Executive Order and July letters to 17 firms, pressuring an end to “global freeloading” on U.S.-funded innovation.
“We're not subsidizing the world anymore. These deals deliver massive savings directly to American patients.”
By
HB Team
